Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL182687 | 0.82 | LMNA (0.41) | GPR35TSHRLMNAKDM4EAPEX1 | |
| SCHEMBL3431418 | 0.81 | KCNMA1 (0.43) | GPR35ALDH1A1KCNMA1TSHRKMT2A | |
| SCHEMBL546991 | 0.79 | NPSR1 (0.43) | ALDH1A1KCNMA1TSHRVCAM1KMT2A | |
| SCHEMBL10240268 | 0.78 | GPR35 (0.34) | GPR35ALDH1A1KCNMA1TSHRKMT2A | |
| SCHEMBL13375198 | 0.78 | ALDH1A1 (0.40) | GPR35ALDH1A1KMT2AHTTLMNA | |
| SCHEMBL7514225 | 0.78 | KMT2A (0.49) | GPR35ALDH1A1KMT2AHTTLMNA | |
| Hydrochloric Acid SCHEMBL3467163 | 0.78 | NPSR1 (0.42) | ALDH1A1KCNMA1TSHRVCAM1KMT2A | |
| Propane SCHEMBL18131179 | 0.77 | HCAR3 (0.38) | ALDH1A1TSHRLMNAKDM4EMAPT | |
| SCHEMBL13543760 | 0.77 | SLC6A2 (0.40) | ALDH1A1KCNMA1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL7760011 | 0.76 | PRSS1 (0.39) | GPR35ALDH1A1KCNMA1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111902400-B | Aromatic derivatives, process for their preparation and their medical use | 保仕健生物科技(上海)有限公司 | 2024-08-30 | — | — | CN | disclosed |
| US-11976058-B2 | Aromatic derivatives, preparation methods, and medical uses thereof | BIOARDIS LLC (US) | 2024-05-07 | — | — | US | disclosed |
| EP-3150592-B1 | ALK KINASE INHIBITOR, AND PREPARATION METHOD AND USE THEREOF | SHANGHAI EMERALD WELLCARES PHARMACEUTICAL CO LTD (CN) | 2023-08-30 | — | — | EP | disclosed |
| CN-112047932-B | Pyrazole spleen tyrosine kinase inhibitor and preparation method and application thereof | 中国药科大学 | 2022-11-08 | — | — | CN | disclosed |
| CN-110997637-B | Aromatic derivative, preparation method and application thereof in medicine | 保仕健生物科技(上海)有限公司 | 2022-09-27 | — | — | CN | disclosed |
| US-20220169634-A1 | AROMATIC DERIVATIVES, PREPARATION METHODS, AND MEDICAL USES THEREOF | BIOARDIS LLC | 2022-06-02 | — | — | US | disclosed |
| EP-3935048-A1 | AROMATIC DERIVATIVES, PREPARATION METHODS, AND MEDICAL USES THEREOF | Bioardis LLC (US) | 2022-01-12 | — | — | EP | disclosed |
| CN-112047932-A | Pyrazole spleen tyrosine kinase inhibitor and preparation method and application thereof | 中国药科大学 | 2020-12-08 | — | — | CN | disclosed |
| CN-111902400-A | Aromatic derivatives, process for their preparation and their medical use | 保仕健生物科技(上海)有限公司 | 2020-11-06 | — | — | CN | disclosed |
| CN-110997637-A | Aromatic derivative, preparation method and application thereof in medicine | 博奥阿迪斯生物科技公司 | 2020-04-10 | — | — | CN | disclosed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2010-10-14 | — | — | US | disclosed |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-09-17 | — | — | US | disclosed |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-26 | — | — | US | disclosed |
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | disclosed |
| US-6897208-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | disclosed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | CDK9, BMX, SBK3 | GPR35 3607/4885ALDH1A1 1389/4885KCNMA1 722/4885 |
| US-11976058-B2 | Aromatic derivatives, preparation methods, and medical uses thereof | FGFR4, FGFR3, FGFR1 | GPR35 1402/4885ALDH1A1 876/4885KCNMA1 4615/4885 |
| US-20040048868-A1 | Benzimidazoles | CDK9, BMX, CDKN1A | GPR35 3990/4885ALDH1A1 862/4885KCNMA1 322/4885 |
| US-20220169634-A1 | AROMATIC DERIVATIVES, PREPARATION METHODS, AND MEDICAL USES THEREOF | FGFR4, FGFR3, FGFR1 | GPR35 1402/4885ALDH1A1 876/4885KCNMA1 4615/4885 |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | GPR35 923/4885ALDH1A1 1930/4885KCNMA1 4583/4885 |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | GPR35 923/4885ALDH1A1 1930/4885KCNMA1 4583/4885 |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | GPR35 923/4885ALDH1A1 1930/4885KCNMA1 4583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.